188 related articles for article (PubMed ID: 19200013)
1. Procedure for identification and characterization of drugs efficient against mammalian prion: from a yeast-based antiprion drug screening assay to in vivo mouse models.
Voisset C; Saupe SJ; Galons H; Blondel M
Infect Disord Drug Targets; 2009 Feb; 9(1):31-9. PubMed ID: 19200013
[TBL] [Abstract][Full Text] [Related]
2. Protein folding activity of the ribosome (PFAR) -- a target for antiprion compounds.
Banerjee D; Sanyal S
Viruses; 2014 Oct; 6(10):3907-24. PubMed ID: 25341659
[TBL] [Abstract][Full Text] [Related]
3. A yeast-based assay to isolate drugs active against mammalian prions.
Bach S; Tribouillard D; Talarek N; Desban N; Gug F; Galons H; Blondel M
Methods; 2006 May; 39(1):72-7. PubMed ID: 16750390
[TBL] [Abstract][Full Text] [Related]
4. Antihypertensive drug guanabenz is active in vivo against both yeast and mammalian prions.
Tribouillard-Tanvier D; Béringue V; Desban N; Gug F; Bach S; Voisset C; Galons H; Laude H; Vilette D; Blondel M
PLoS One; 2008 Apr; 3(4):e1981. PubMed ID: 18431471
[TBL] [Abstract][Full Text] [Related]
5. Systematic identification of antiprion drugs by high-throughput screening based on scanning for intensely fluorescent targets.
Bertsch U; Winklhofer KF; Hirschberger T; Bieschke J; Weber P; Hartl FU; Tavan P; Tatzelt J; Kretzschmar HA; Giese A
J Virol; 2005 Jun; 79(12):7785-91. PubMed ID: 15919931
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a class of diketopiperazines as antiprion compounds.
Bolognesi ML; Ai Tran HN; Staderini M; Monaco A; López-Cobeñas A; Bongarzone S; Biarnés X; López-Alvarado P; Cabezas N; Caramelli M; Carloni P; Menéndez JC; Legname G
ChemMedChem; 2010 Aug; 5(8):1324-34. PubMed ID: 20540064
[TBL] [Abstract][Full Text] [Related]
7. Unique drug screening approach for prion diseases identifies tacrolimus and astemizole as antiprion agents.
Karapetyan YE; Sferrazza GF; Zhou M; Ottenberg G; Spicer T; Chase P; Fallahi M; Hodder P; Weissmann C; Lasmézas CI
Proc Natl Acad Sci U S A; 2013 Apr; 110(17):7044-9. PubMed ID: 23576755
[TBL] [Abstract][Full Text] [Related]
8. Protein folding activity of ribosomal RNA is a selective target of two unrelated antiprion drugs.
Tribouillard-Tanvier D; Dos Reis S; Gug F; Voisset C; Béringue V; Sabate R; Kikovska E; Talarek N; Bach S; Huang C; Desban N; Saupe SJ; Supattapone S; Thuret JY; Chédin S; Vilette D; Galons H; Sanyal S; Blondel M
PLoS One; 2008 May; 3(5):e2174. PubMed ID: 18478094
[TBL] [Abstract][Full Text] [Related]
9. The toll-like receptor agonist imiquimod is active against prions.
Oumata N; Nguyen PH; Beringue V; Soubigou F; Pang Y; Desban N; Massacrier C; Morel Y; Paturel C; Contesse MA; Bouaziz S; Sanyal S; Galons H; Blondel M; Voisset C
PLoS One; 2013; 8(8):e72112. PubMed ID: 23977222
[TBL] [Abstract][Full Text] [Related]
10. Structural insight into the antiprion compound inhibition mechanism of native prion folding over misfolding.
Choi J; Govindaraj RG; Hyeon JW; Lee K; Ma S; Kim SY; Lee J; No KT
Chem Biol Drug Des; 2017 Jun; 89(6):907-917. PubMed ID: 27933736
[TBL] [Abstract][Full Text] [Related]
11. Variety of antiprion compounds discovered through an in silico screen based on cellular-form prion protein structure: Correlation between antiprion activity and binding affinity.
Hosokawa-Muto J; Kamatari YO; Nakamura HK; Kuwata K
Antimicrob Agents Chemother; 2009 Feb; 53(2):765-71. PubMed ID: 19015328
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the antiprion activity of 6-aminophenanthridines and related heterocycles.
Nguyen P; Oumata N; Soubigou F; Evrard J; Desban N; Lemoine P; Bouaziz S; Blondel M; Voisset C
Eur J Med Chem; 2014 Jul; 82():363-71. PubMed ID: 24927056
[TBL] [Abstract][Full Text] [Related]
13. SPR biosensor as a tool for screening prion protein binders as potential antiprion leads.
Chen B
Methods Mol Biol; 2010; 627():147-55. PubMed ID: 20217619
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 2-aminothiazoles as potent antiprion compounds.
Ghaemmaghami S; May BC; Renslo AR; Prusiner SB
J Virol; 2010 Apr; 84(7):3408-12. PubMed ID: 20032192
[TBL] [Abstract][Full Text] [Related]
15. Animal models for testing anti-prion drugs.
Fernández-Borges N; Elezgarai SR; Eraña H; Castilla J
Curr Top Med Chem; 2013; 13(19):2504-21. PubMed ID: 24059334
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationship study around guanabenz identifies two derivatives retaining antiprion activity but having lost α2-adrenergic receptor agonistic activity.
Nguyen PH; Hammoud H; Halliez S; Pang Y; Evrard J; Schmitt M; Oumata N; Bourguignon JJ; Sanyal S; Beringue V; Blondel M; Bihel F; Voisset C
ACS Chem Neurosci; 2014 Oct; 5(10):1075-82. PubMed ID: 25244284
[TBL] [Abstract][Full Text] [Related]
17. Antiprion drugs as chemical tools to uncover mechanisms of prion propagation.
Tribouillard D; Gug F; Galons H; Bach S; Saupe SJ; Blondel M
Prion; 2007; 1(1):48-52. PubMed ID: 19164923
[TBL] [Abstract][Full Text] [Related]
18. New approaches for the selection and evaluation of anti-prion organic compounds.
Cordeiro Y; Ferreira NC
Mini Rev Med Chem; 2015; 15(2):84-92. PubMed ID: 25723455
[TBL] [Abstract][Full Text] [Related]
19. Discovery of small molecules binding to the normal conformation of prion by combining virtual screening and multiple biological activity evaluation methods.
Li L; Wei W; Jia WJ; Zhu Y; Zhang Y; Chen JH; Tian J; Liu H; He YX; Yao X
J Comput Aided Mol Des; 2017 Dec; 31(12):1053-1062. PubMed ID: 29159521
[TBL] [Abstract][Full Text] [Related]
20. Mode of action of the antiprion drugs 6AP and GA on ribosome assisted protein folding.
Reis SD; Pang Y; Vishnu N; Voisset C; Galons H; Blondel M; Sanyal S
Biochimie; 2011 Jun; 93(6):1047-54. PubMed ID: 21396977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
